Bayer's €375 Million Stivarga Sale Clears the Decks While Missouri Judge Weighs a $7.25 Billion Finale
Published on 09/22/2026 at 15:12 | Editorial boerse-global.de
Bayer has quietly been tidying up its portfolio at the same time as it awaits the most consequential legal ruling in its recent history. The Leverkusen-based group agreed yesterday, according to media reports, to hand worldwide rights to its cancer drug Stivarga to Grünenthal, a deal worth as much as EUR 375 million that adds breathing room to the balance sheet. The transaction is small in the context of Bayer's overall footprint, but it lands at a moment when every euro of financial flexibility counts.
That is because a far weightier matter is now in the hands of a single judge. On 14 September, Monsanto filed a motion before a court in the US state of Missouri seeking approval of a $7.25 billion settlement aimed at resolving a substantial portion of the sprawling legal complex surrounding its glyphosate-based weedkiller. Reuters reports that the agreement is designed to close out tens of thousands of US claims, with structured payouts ranging from $10,000 to $165,000 for certain plaintiffs.
A stock that has already priced in a lot of hope
Equity investors have not been idle while the paperwork moves through the courts. Bayer shares have climbed 33% since the start of the year, changing hands at EUR 49.32. That rally reflects a market that has grown more comfortable with the idea that the worst of the litigation may soon be behind the company. Whether that optimism is justified is the question now hanging over the stock.
The arithmetic is straightforward enough. A confirmed settlement would remove the single largest valuation discount that has dogged Bayer for years, freeing management to focus on operations rather than courtroom strategy. A rejection, or even a prolonged delay, would leave the liabilities as opaque as ever and could unravel the gains of recent months in short order.
Should investors sell immediately? Or is it worth buying Bayer?
What the court must decide
US judges do not rubber-stamp mass settlements. They scrutinise them closely, particularly on the question of whether future or dissenting claims are adequately protected. The proposed payout bands of $10,000 to $165,000 could themselves become a flashpoint: plaintiffs who consider those sums insufficient may choose to pursue their cases individually rather than sign on. If a meaningful number of claimants walk away, the risk of further costly trials is not extinguished.
Should the Missouri court deny the motion, demand revisions, or allow objections from plaintiffs' attorneys, Bayer would be back at square one. The $7.25 billion would cease to function as a genuine line in the sand, and the fear of an open-ended wave of litigation would return to the market immediately. Legal costs would keep accruing, and the prospect of unpredictable jury awards would once again weigh on refinancing costs and on the company's ability to invest in crop science and pharmaceutical research.
The other side of the ledger
A green light from the judge would change the narrative materially. With the heaviest legal overhang lifted, remaining litigation risks would shrink to a manageable scale and Bayer could begin to reclaim a more normal valuation premium. Proceeds from disposals such as Stivarga could then be channelled directly into debt reduction.
The pharmaceutical pipeline has meanwhile been delivering. Bayer secured two US approvals: accelerated FDA clearance for Sevabertinib as a first-line treatment for HER2-mutant non-small cell lung cancer, and a green light for Finerenon in chronic kidney disease associated with type 1 diabetes. The FDA also broadened the Kerendia label more than a month ago. In agriculture, the subsidiary Robigo and Leaps by Bayer announced a Series A financing aimed at developing genetically engineered biological products designed to protect yields and lower farming costs. In a calmer legal environment, such milestones would carry far more weight with investors.
Bayer at a turning point? This analysis reveals what investors need to know now.
The catalyst that matters most
For now, positioning in the stock comes down to a single variable. As long as the path toward confirmation of the settlement remains intact and the market continues to believe in legal closure, the valuation premium is supported. If the approval process before the Missouri Circuit Court stalls or collapses, a sharp loss of confidence could erase the year's advance.
The next hard catalyst is the court's ruling, expected at some point after the 14 September hearing. Until that decision lands, Bayer remains a stock whose fate is being decided as much in a courtroom as on the operating table.
Ad
Bayer Stock: New Analysis - 22 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
